# Zofia Piotrowska
**Type:** Researchers
**Canonical URL:** https://scholariq.org/researchers/zofia-piotrowska/
## Facts
| Field | Value |
| --- | --- |
| Citations | 10,797 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 43 |
| i10-index | 103 |
| Last Known Institution | Massachusetts General Hospital |
| OpenAlex ID | https://openalex.org/A5069070706 |
| ORCID iD | 0000-0002-9008-8573 |
| Works | 352 |
## Researcher papers
- [EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis](https://scholariq.org/papers/i-egfr-i-mutations-and-i-alk-i-rearrangements-are-associated-with-low-response/)
- [Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition](https://scholariq.org/papers/tumor-cells-can-follow-distinct-evolutionary-paths-to-become-resistant-to/)
- [Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/rociletinib-in-i-egfr-i-mutated-non-small-cell-lung-cancer/)
- [Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients](https://scholariq.org/papers/circulating-tumour-dna-profiling-reveals-heterogeneity-of-egfr-inhibitor/)
- [The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies](https://scholariq.org/papers/the-allelic-context-of-the-c797s-mutation-acquired-upon-treatment-with-third/)
- [EGFR -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes](https://scholariq.org/papers/i-egfr-i-mutant-adenocarcinomas-that-transform-to-small-cell-lung-cancer-and/)
- [Heterogeneity Underlies the Emergence of EGFR T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor](https://scholariq.org/papers/heterogeneity-underlies-the-emergence-of-i-egfr-i-t790-wild-type-clones/)
- [Landscape of Acquired Resistance to Osimertinib in EGFR -Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion](https://scholariq.org/papers/landscape-of-acquired-resistance-to-osimertinib-in-i-egfr-i-mutant-nsclc-and/)
- [Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms](https://scholariq.org/papers/three-subtypes-of-lung-cancer-fibroblasts-define-distinct-therapeutic-paradigms/)
- [Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/patterns-of-metastatic-spread-and-mechanisms-of-resistance-to-crizotinib-in-i/)
- [Complete evaluation of resistance mechanisms to first-line osimertinib requires tissue biopsy.](https://scholariq.org/papers/complete-evaluation-of-resistance-mechanisms-to-first-line-osimertinib-requires/)
- [Clinical outcomes of EGFR+ NSCLC pts treated with immune checkpoint inhibitors (ICI).](https://scholariq.org/papers/clinical-outcomes-of-egfr-nsclc-pts-treated-with-immune-checkpoint-inhibitors/)
## Researcher topics
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
## Researcher university
- [Massachusetts General Hospital](https://scholariq.org/institutions/massachusetts-general-hospital/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.